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Abstract
Purpose: The management of bone defects following simple curettage of bone tumors is controversial and in light of the
numerous emerging substitutes for bone grafts, we wished to review and report our experience with the use of cancellous
allograft bone in the treatment of benign and borderline bone tumors. Methods: We reviewed the medical records of
164 consecutive patients with benign or borderline bone tumors treated with simple curettage at our orthopedic
oncology center between 2009 and 2013. Postoperative radiological changes were evaluated by a modified Neer’s
classification in defects that were subsequently reconstructed with allograft bone (n ¼ 133). Results: Simple curettage
with subsequent defect filling using allograft bone was the surgical procedure performed in the majority of our
patients (81%) and was associated with a low overall 2.5-year local recurrence (LR; 9.8%) and complication rate (7.5%).
The radiological appearance of the grafted defects was deemed satisfactory in 85% of cases, with signs of either
complete or partial healing present 6–12 months postoperatively. With respect to pathology, we found high rates of
LR in giant cell tumors (GCTs) of bone, simple cysts (SCs) in children, and preexisting local recurrent disease. We
did not observe any allograft-related complications. Conclusions: Simple curettage and bone defect reconstruction
with bone allograft is a sufficient treatment for most benign bone lesions and is associated with a low complication rate.
For high-risk entities, such as GCTs of bone, SCs in children, and recurrent disease, additional adjuvant treatment could be
considered to avoid LR.
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Introduction
Simple curettage is the most common surgical treatment for
benign bone tumors1–3 and has been reported as an accep-
table method associated with relatively low recurrence
rates, even for the treatment of low-grade chondrosarcomas
(CS).4,5 The management of subsequent bone defect, how-
ever, remains controversial and treatment options vary
greatly from no treatment to use of various filling
materials.6 While satisfactory clinical results have also
been shown in defects without grafting,7,8 residual fracture
risk remains a concern as natural bone healing may not be
sufficient for all bone defects beyond a certain size.
Autogenous cancellous bone is still widely considered the
gold standard for the reconstruction of bone defects, due to
its potential osteogenetic, osteoinductive, and osteo-
conductive abilities. However, due to its well-known
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disadvantages, including donor site morbidity, prolonged
operating time, and limited availability, it is often augmen-
ted with—or replaced by—allografts, bone cements, or
bone graft substitutes, particularly for larger reconstruc-
tions.9–11 Traditionally, cancellous allograft bone has
been the graft material of choice for bone defect recon-
struction at our institution for many years, and although
curettage and bone grafting is commonly used for the
treatment of contained defects in orthopedic tumor sur-
gery in general, only limited data on clinical results and
complication rates have been published during recent
years (Figure 1). With a view to eventually compare the
performance of newer bone graft substitutes to conven-
tional bone grafting in the future, we wished to review and
report our experience with the use of simple curettage
and cancellous allograft bone in the treatment of benign
and borderline bone tumors and cysts.
Materials and methods
Study design and patient population
We performed a retrospective review of all patients treated
with curettage for benign or borderline bone tumors and
cysts in our orthopedic oncology department between
January 1, 2009, and December 31, 2013. All relevant data
(age, gender, histological diagnosis, grade, size and anato-
mical location of the lesion, details of the surgical proce-
dure, use of orthopedic implants, weight bearing status,
occurrence of postoperative complications, and local recur-
rence (LR)) were collected from the medical records, the
national pathology database,12 and the national country-
wide electronic patient file system. We identified 164
patients (M/F¼ 79/85, median age¼ 29 (2–70) years) with
a minimum follow-up of 2.7 years (median 5.0 (2.7–7.6)
years), who had undergone simple curettage for their
Figure 1.Upper row: (a) Preoperative X-ray of a GCT in the proximal tibia of a 29-year-old female. (b) Immediate postoperative X-ray
confirms complete defect filling with bone graft. (c) X-ray 1 year postoperatively displays graft integration with small radiolucent areas
below the lateral subchondral plate and the tibial eminence (MNC grade 2). (d) 5 years postoperatively, the defect appears completely
healed (MNC grade 1). Lower row: (e) Preoperative X-ray of FD in the proximal ulna of a 15-year-old girl. (f) Immediate postoperative
X-ray shows complete defect filling. (g) X-ray 1 year postoperatively displays complete graft integration (MNC grade 1) and beginning
cortical consolidation. (h) X-ray 2 years postoperatively shows signs of progressive graft integration and remodeling. GCT: giant cell
tumor; FD: fibrous dysplasia. MNC: Modified Neer’s Classification.
2 Journal of Orthopaedic Surgery 26(3)
primary (n ¼ 151/164 (92%)) or recurrent (n ¼ 13/164
(8%)) bone lesion. We calculated the time to LR, defined
as the time from the date of the initial intervention to the
date of histological verification of the LR, and time to
unrestricted weight bearing (UWB), defined as the time
from operation until permission of UWB by the surgeon,
based on clinical and/or radiological examination as a sur-
rogate measure of clinical healing.
Bone lesion characteristics and surgical intervention
The reasons for initial presentation were either local symp-
toms (n¼ 148/164 (90%)) or a pathologic fracture (n¼ 16/
164 (10%)). With respect to anatomical location, approxi-
mately two-thirds of the bone tumors in our cohort were
situated in the lower extremity (n ¼ 105/164 (64%)). The
most common histopathological diagnosis encountered was
enchondromas, comprising almost half of the study popu-
lation, followed by simple (unicameral bone) cysts (SCs),
aneurysmal bone cysts (ABCs), fibrous dysplasia (FD), and
giant cell tumors (GCTs) of bone. The cohort also included
four cases of low-grade CS treated by simple curettage
(Table 1). We calculated the size of the lesion by approx-
imating measures from computed tomography (CT)/mag-
netic resonance imaging to a spherical shape (height 
width  length  0.52).7 All lesions were graded with
respect to radiological appearance and deemed structural
integrity using a modified Campanacci classification.3
Accordingly, from a radiological and structural perspec-
tive, the residual walls of the defects were intact (grade
1) in 72 of 164 (45%) lesions, thinned (grade 2) in 74 of
164 (45%) lesions, and deficient or breached (grade 3) in 18
of 164 (11%) lesions, with an estimated mean residual bone
defect volume after tumor curettage of 11.5 (0.1–94) mL.
Cancellous allograft was used for bone defect reconstruc-
tion in the majority of the cases (n¼ 133/164; 81%). In four
cases of small metacarpal or phalangeal bone defects, auto-
graft harvested from the distal radius was chosen as filling
material, and a bone graft substitute (HydroSet™, Stryker
Corp, MA, USA: n ¼ 5 or Cerament™|Bone Void Filler,
Bonesupport AB, Lund, Sweden: n ¼ 1) was used in six
other locations due to small defect size or nonavailability of
allograft bone. In 21 small lesions, deemed structurally
irrelevant (modified Campanacci grade 1, n ¼ 13), located
in the hand (n ¼ 9), or other non-weight bearing locations
(n ¼ 3), the bone defect was left empty at the discretion of
the individual surgeon. In lesions that were deemed struc-
turally impaired or at risk, mechanical augmentation with
internal fixation, using either plates (n ¼ 16/164 (10%)) or
intramedullary nails (n ¼ 4/164 (2%)), was performed in
addition to the bone defect reconstruction.
Radiological evaluation
X-rays of the bone defects were classified according to a
modified Neer’s classification of radiological bone cyst
appearance (Table 2).13,14
Statistical analysis and approvals
We applied Kaplan–Meier survival analysis to estimate the
cumulative incidence function (time to event) for the out-
come of interest (LR) with calculation of 95% confidence
intervals (95% CI) and log-rank test using SPSS software
(version 22). Approval for the study was obtained from the
Danish Data Protection Agency (J.no. 2014-41-3021) and
Table 1. Histology and number of LRs of the surgically treated
bone tumors and cysts.
Primary tumor No. LR, n (n%)
Enchondroma 57 2 (4%)
SC (adult) 20
ABC 15
FD 14 2 (14%)
GCT 12 4 (33%)
Chondroblastoma 6 1 (17%)
SC (child) 10 4 (40%)
Non-ossifying fibroma 5 1 (20%)
Intraosseous ganglion 5 1 (20%)
Osteoid osteoma 5 2 (40%)
CS grade I 4
Langerhans cell histiocytosis 2 1 (50%)
Chondromyxoid fibroma 1
Epithelioid hemangioma 1
Giant cell granuloma 1
Intraosseous myofibroma 1 1 (100%)
Other 5
LR: local recurrence; SC: simple cyst; ABC: aneurysmal bone cyst; FD:
fibrous dysplasia; GCT: giant cell tumor; CS: chondrosarcoma.
Table 2.Modified Neer classification of radiological evaluation of
bone defect healing.
Score Classification Description
I Complete healing Complete or almost completea filling
of the initial lesion with radiological
evidence of new bone formation
II Partial healing Incomplete healing and/or graft
resorption in an area(s) less than
50% of the initial lesion with enough
cortical thickness to prevent
fracture
III Persistent lesion Graft resorption or persistent
radiolucent area(s) greater than 50%
of the initial lesion and/or with a thin
cortical rim potentially at risk for
fracture
IV Recurrent lesion Progressive lesion reappeared in a
previously obliterated area or a
residual radiolucent area verified by
biopsy
aWith or without small nonprogressive radiolucent area(s) less than 1 cm
in size.
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Department of Health Agency (J.no. 3-3013-705/1). For
this type of study, formal consent was not required.
Results
Local recurrence
LR occurred in 19 of 164 patients (11.6%), most commonly
among GCT (n ¼ 4/12 (33%)) and SC (n ¼ 4/10 (40%)) in
children (Table 1). Most recurrences (n ¼ 14/19 (74%))
occurred within the first 2.5 years and the overall cumula-
tive incidence was 8.5% (95% CI: 4.1–12.9%; Figure 2).
For patients whose defects were treated with allograft bone,
the overall 2.5-year cumulative incidence was 9.8% (95%
CI: 4.6–15%). Among SC in adults or enchondromas, no
LR was observed within the first 2.5 years, whereas SC in
children had a high (p ¼ 0.002) 2.5-year cumulative inci-
dence of 40% (95% CI: 9.0–71.0%; Figure 2). As expected,
LR was more common (p¼ 0.002) for preexisting recurrent
disease compared to primary disease with 2.5-year
cumulative incidences of 30.8% (95% CI: 5.2–56.4%)
and 6.6% (95% CI: 2.6–10.6%), respectively (Figure
2). It is worth mentioning that LR was least common
in adult SC (0%), ABC (0%), and benign or borderline
cartilaginous tumors, that is, enchondromas (n ¼ 2/57
(4%)) or low-grade CS (0%).
Time to UWB
Immediate postoperative UWB could be permitted in the
majority of cases (n ¼ 100/164; 61%). For the remaining
patients (n ¼ 64/164; 39%), UWB was allowed after a
median of 5.9 (2–21) and 6.0 (2–21) weeks for patients
treated with allograft (n ¼ 53/164; 32%). Restriction of
UWB beyond 6 weeks was typically recommended to
patients with larger tumors (mean volume: 24 (0.1–94)
mL) located in the lower extremity (n ¼ 26/31). Plate or
nail augmentation was used in 20 cases, most commonly
(n¼ 15/20) in the proximal femur, and in 13 of these cases,
immediate postoperative UWB was permitted. For the
remaining seven patients augmented with plate or nail,
UWB was allowed after a mean of 10 (6–21) weeks.
Radiological evaluation
Postoperative follow-up X-rays were available in 131 of the
133 patients treated with allograft bone. Mean radiological
follow-up was 19 (1–84) months, however, only 73 patients
with either larger tumors than average (mean volume: 19.1
(0.5–95) mL), tumor location in the lower extremity
(n ¼ 55), and entities with tendency to LR (n ¼ 46) were
followed radiologically for more than 6 months. Evaluation
of the immediate postoperative X-rays revealed incomplete
defect filling in 24 of 131 cases (18%) and complete filling
in 107 cases (82%). After 6–12 months postoperatively
(n ¼ 73), 38 defects appeared completely filled (grade 1),
24 had minor defects (grade 2), 6 had larger defects (grade
3), and 5 had recurrent disease (grade 4; Figure 3). While
the grade of filling remained unchanged in 45 cases during
the follow-up period, incomplete postoperative filling
further consolidated to complete filling in only 3 cases or
decreased in other 3 cases. Deterioration of complete initial
defect filling due to graft resorption was observed in 17
cases (grade 2: n ¼ 14 and grade 3: n ¼ 3) and due to
LR in 5 cases (Figure 4). Of the 21 empty defects, only
four patients had radiological follow-up for more than
6 months and in two of these cases (both small chondro-
blastomas in the distal femur of children), the defect dis-
played signs of bone healing with defect filling >50%
(grade 2).
Postoperative complications
Complications occurred in 11 of 164 patients (7%) with
postoperative infection (n ¼ 3), postoperative fracture
(n ¼ 2), and nerve palsy (n ¼ 2) being the most common
Figure 2. Kaplan–Meier survival analyses displaying LR-free survival following curettage of benign bone tumors and cysts. Left:
displaying overall LR-free survival. Middle: comparing recurrence-free survival, SC in children (blue) and SC in adults (green). Right:
comparing recurrence rate for primary disease (blue) with recurrent disease (green). LR: local recurrence; SC: simple cyst.
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(Table 3). All but one complication (transient peroneal
nerve palsy after curettage of a proximal fibula intraoss-
eous ganglion filled with a bone graft substitute; Hydro-
set™, Stryker) occurred in patients treated with allograft
bone (n ¼ 10/133 (8%)). One deep infection occurred after
plate augmentation of a SC (16 mL) in the proximal femur.
Two superficial infections occurred after simple curettage
and grafting of a small (4 mL) enchondroma in the distal
femur and curettage and grafting of a SC in the proximal
femur, treated with temporary external fixation for stabili-
zation of a pathological fracture. Postoperative fracture
occurred after removal of a large (22 mL) intraosseous
myofibroma in the calcaneus and after removal of an
enchondroma (11 mL) in the distal femur. The latter
patient also developed postfracture deep venous thrombo-
sis. Transient neurapraxia of the peroneal nerve followed
curettage of a recurrent intraosseous ganglion in the prox-
imal fibula, and persistent radial nerve damage followed
curettage of a large (75 mL) humeral diaphyseal bone cyst
that had previously fractured and healed in malalignment.
Minor pulmonary embolism occurred following curettage
of FD affecting the proximal femur of a 40-year-old
woman. All wound healing–related complications
occurred in the foot, delayed wound healing following
curettage of a SC in the calcaneus and a GCT in talus,
respectively, and one skin necrosis following curettage of
osteoid osteoma in the talus.
Discussion
Although the differential treatment of benign bone lesions
has evolved considerably during the past two decades, the
goals of treatment remain to establish a correct diagnosis,
completely remove the lesion, and to relieve pain if present,
while preserving and/or restoring function and minimizing
complications. While emerging minimally invasive tech-
niques such as radiofrequency ablation, embolization, and
percutaneous injection techniques are gaining importance
for certain entities, our results indicate that simple curet-
tage remains an adequate treatment option for a wide spec-
trum of indications, particularly those with low risk of LR,
such as enchondromas, where the expected rate of LR is
almost nonexistent even without the use of any local adju-
vants.4,5 Despite the promising surgical results, nonopera-
tive treatment and radiological follow-up should be
considered for patients with non-symptomatic enchondro-
mas, hereby avoiding the risks of open surgery.15 Extended
curettage with adjuvant treatment, on the other hand,
should be considered in high-risk entities such as GCTs
of bone, where the risk of LR could be as high as 50% if
treated without adjuvants.16 Our results also confirm pre-
vious reports that SCs in children display recurrence rates
comparable to GCT’s,17,18 which is why this particular
patient group deserves also special attention and consider-
ation of suitable adjuvant treatment.
Surprisingly, little data are published to guide surgeons
whether reconstruction of a bone defect resulting from sur-
gical removal of a benign bone lesion is indicated and how
this is technically best accomplished. Furthermore, no pre-
cise objective criteria exist to determine when a bone defect
is sufficiently healed to withstand the risk of fracture. Con-
sequently, these decisions are based on clinical judgment,
rather than objective factors. Although Wolff’s law indi-
cates that healthy bone naturally adapts to load-bearing, it
cannot predict the speed of bone healing or determine
which bone defects are too large for spontaneous bone
healing. Therefore, the degree of radiographic consolida-
tion observed in a bone defect may well be important to
guide the physician to evaluate a persisting risk of fracture,
especially in case of insufficient spontaneous bone healing.
Two recent articles demonstrate that most patients treated
without bone defect reconstruction regain full weight bear-
ing capacity and that bone defects consolidate without aug-
mentation with bone graft.7,8 While the clinical results
reported in these two studies are comparable with those
observed in our cohort, the reported fracture rates (3.8%
and 10%, respectively) are considerably higher than the
fracture rate observed in our study (1.5%). There was a
tendency in both studies that larger defects were associated
with higher complication rates, which indicates that the
omission of bone defect reconstruction may not lead to
an increase in absolute fracture risk per se, but depends
on other factors such as the relative defect size, anatomical
location, as well as the extent of presence or absence of
spontaneous bone healing of the individual defect. As the
compressive strength of bone allograft is poor, the potential
increase in structural integrity by grafting a bone defect is
unlikely to be the explanation for the observed differences
in fracture rates.
Our rationale for bone grafting was mainly to enhance
bone healing by providing an osteoconductive scaffold. A
study that examined untreated cavitary bone defects with
CT 1 year postoperatively found evidence of compensatory
Figure 3. Radiological evaluation based on a modified Neer’s
classification (Table 2) in patients treated with bone allograft
and more than 6 months of radiological follow-up.
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cortical thickening, but no or very little evidence of spon-
taneous bone formation within the actual cavity itself.8 In
contrast, results from another study on treatment of
metaphyseal bone defects with impaction grafting using
cancellous allograft bone as an adjunct to osteosynthesis
of tibial plateau fractures in osteoporotic patients con-
firmed that the majority of the bone graft (mean: 55%)
showed evidence of remodeling into trabecular bone with
a normal radiological appearance on X-ray and CT after
1 year, while 37% remained unremodeled, and only 8% had
resorbed.19 These results are comparable to our radiologi-
cal findings, which may indicate that unchanged X-ray
appearance could be perceived as an indirect sign of at least
partial graft integration. Furthermore, these results also
support the rationale for the use of osteoconductive scaf-
folds, such as bone allografts or bone graft substitutes,
Figure 4. Upper row: (a) Preoperative X-ray of a pathologic fracture through a large bone cyst affecting the proximal femur in a
10-year-old boy. (b) Immediate postoperative X-ray after ORIF and bone grafting displays anatomical reduction, locking plate fixation,
and complete defect filling. (c) X-ray 3 months postoperatively confirms consolidation of the fracture. (d) X-ray 6 months post-
operatively shows significant graft resorption and early signs of LR in the medial subtrochanteric region with increasing radiolucency and
cortical thinning. (e) 1 year postoperatively, complete resorption of all previously implanted allograft is evident. Due to substantial
progression of local cyst recurrence, reoperation with implant removal and repeat grafting was indicated. Lower row: (f) Immediate
post reoperation X-ray shows complete defect filling after implant removal. (g) 15 months postoperatively, graft integration appears
radiographically complete (MNC grade 1) and both cortices show signs of consolidation. (h) X-ray 2 years postoperatively displays
significant graft resorption over 50% (MNC grade 3). (i) 3 years postoperatively, there is evidence of progressive graft integration and
remodeling with only small radiolucent areas in the central portions of the defect (MNC grade 2). (j) 4 years postoperatively, the natural
course of graft integration and remodeling appears almost complete without residual lucent areas (MNC grade 1) and substantial
consolidation of all previously involved cortices. LR: local recurrence; ORIF: open reduction and internal fixation.
Table 3. Complications.
Type No.
Infection (1 deep/2 superficial) 3
Fracture 2
Nerve injury 2
Delayed wound healing 2
Deep venous thrombosis 1
Lung embolism 1
Skin necrosis and re-suturing 1
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which may contribute to a more complete bone cavity remo-
deling. Bearing in mind the relatively rare complications
associated with bone allografts, such as immunogenic reac-
tions, disease transmission, and risk of infection,9–11,20 it is
not surprising that we did not observe any true allograft-
related complications; however, our study sample is of course
far too small for any meaningful conclusion in this regard.
The main limitation of this study is the lack of complete
clinical and radiological follow-up in all patients and the use
of an indirect outcome measure (UWB) as a surrogate for
clinical bone healing, which of course does not reflect actual
bone healing. Although the study is retrospective, our
nationwide electronic patient file system made it possible
to detect admissions and treatments at other hospitals to
complement our own patient file, leading to very little or
no loss of information regarding serious complications,
recurrences, and reoperations, which otherwise could have
led to underestimation of complication and recurrence rates.
Conclusion
Simple curettage and bone defect reconstruction with can-
cellous allograft bone is a good treatment option for many
benign bone lesions and is associated with a low complica-
tion rate. Most commonly, the majority of allograft bone
remains clearly visible on X-ray at 6–12 months postopera-
tively, which may indicate at least partial graft integration.
For high-risk entities, such as GCTs of bone, recurrent
disease, and SCs in children, additional adjuvant treatment
should be considered to avoid LR.
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